Report: Elan to shutter South San Francisco complex in public spinoff; Teva pays $26M for Huntington drug program;

 @FierceBiotech: TDM-1's impressive survival rate puts Roche and Genentech on track for FDA approval. More | Follow @FierceBiotech

 @JohnCFierce: MIT finance wiz calls for $30B megafund to back next-gen cancer drugs. More | Follow @JohnCFierce

 @RyanMFierce: Amid hunt for partnerships, AstraZeneca hits the blogosphere with LabTalk. More | Follow @RyanMFierce

> The San Francisco Business Times is reporting that Elan is shuttering its big South San Francisco research center as it preps the public spinout of a new public company. The move to close the facilities will cost Elan $160 million to $180 million. Report

> Teva ($TEVA) says it will pay out $26 million over the next 6 months to sew up rights to NeuroSearch's Huntington's drug Huntexil. The Israeli pharma company also committed to some unspecified milestones in the deal. "Based on the clinical trial evidence to date, we believe Huntexil holds promise for symptomatic relief for HD and merits additional study in late-stage clinical development," commented Michael R. Hayden, Teva's CSO. Release

> Abbott ($ABT) has snagged a new approval to use its rheumatoid arthritis drug Humira for moderate to severe ulcerative colitis. Story

> GTx says it has sold the cancer drug Fareston to ProStrakan for $19 million, clearing the way for GTx to focus on small molecule drug development. Story | ProStrakan release

Pharma News

 @FiercePharma: In Europe, J&J's injectable  wins approval and  gets AML-in-elderly use. More | Follow @FiercePharma

> Herceptin data fends off $1.5B threat to Roche sales. News

> Abbott exec can take comfort in Mylan CEO's degree travails. Article

> Pfizer's Xalkori, Roche's TDM-1 among winners at ESMO. Story

Medical Device News

 @FierceMedDev: Terumo renewed its license of some crucial stent tech from Biosensors International. More | Follow @FierceMedDev

 @MarkHFierce: An FDA panel supports approval for Second Sight's retinal prosthesis. More | Follow @MarkHFierce

 @DamianFierce: API producer Cedarsburg Hauser is expanding its capabilities and betting on a boom in CMO demand. More | Follow @DamianFierce

> Boston Sci gains FDA nod for much-hyped S-ICD. Story

> DNA 'nanoswitch' could support quick, point-of-care Dx. Item

> AdvaMed spotlights an industry in transition. Article

> Stryker names new leader. News

CRO News

> Quintiles considering small acquisitions, CEO says. News

> FDA taps CRO Vince & Associates for $5M bioequivalent contract. Story

> FDA now in charge of clinical trial transparency. Article

> Cedarburg Hauser bets on API boom with plant expansion. Item

Biotech IT News

> AstraZeneca hits the blogosphere with LabTalk. Story

> Genomics outfit puts genetic tests on computers. News

> ChemAxon opens shop in 'heart' of Boston biotech hub. Article

> Medidata advances clinical trials software use in Japan. Item

And Finally... Investigators say that a lethal bacteria in Africa may have been instigated by the spread of HIV on the continent. Release

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.